UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

JAMA : the journal of the American Medical Association, 2009-10, Vol.302 (13), p.1429

2009

Volltextzugriff (PDF)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Breast cancer research : BCR, 2020-05, Vol.22 (1), p.51-51, Article 51

2020

Volltextzugriff (PDF)

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Clinical cancer research, 2013-01, Vol.19 (2), p.500-507

2013

Volltextzugriff (PDF)

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies

JNCI : Journal of the National Cancer Institute, 2015-02, Vol.107 (2), p.1

2015

Volltextzugriff (PDF)

Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

NPJ breast cancer, 2023-12, Vol.9 (1), p.101-101, Article 101

2023

Volltextzugriff (PDF)

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies

Cancer chemotherapy and pharmacology, 2014-12, Vol.74 (6), p.1271-1278

2014

Volltextzugriff (PDF)

Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents

Anti-cancer agents in medicinal chemistry, 2012-11, Vol.12 (9), p.1117

2012

Volltextzugriff (PDF)

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

Pharmacogenomics, 2011-11, Vol.12 (11), p.1535-1543

2011

Volltextzugriff (PDF)

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

Investigational new drugs, 2013-12, Vol.31 (6), p.1559-1567

2013

Volltextzugriff (PDF)

Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells

Cancer chemotherapy and pharmacology, 2010-08, Vol.66 (3), p.575-583

2010

Volltextzugriff (PDF)

Activation of the Antitumor Agent Aminoflavone (NSC 686288) Is Mediated by Induction of Tumor Cell Cytochrome P450 1A1/1A2

Molecular pharmacology, 2002-07, Vol.62 (1), p.143-153

2002

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

Cancer chemotherapy and pharmacology, 2011-09, Vol.68 (3), p.777-786

2011

Volltextzugriff (PDF)

Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans

Clinical cancer research, 2002-09, Vol.8 (9), p.2952-2962

2002

Volltextzugriff (PDF)

Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1

Clinical cancer research, 1999-08, Vol.5 (8), p.2192-2197

1999

Volltextzugriff (PDF)

Abstract P6-04-06: Protein kinase C beta 1 (PKCβ1), a novel drug target of Z-endoxifen, inhibits growth of estrogen receptor positive (ER+) breast cancer via activation of the NF-kB transcription factor RelA

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-04-06

2020

Volltextzugriff (PDF)

Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD2-09-PD2-09

2021

Volltextzugriff (PDF)

Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD8-04-PD8-04

2021

Volltextzugriff (PDF)

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2017-10, Vol.35 (30), p.3391-3400

2017

Volltextzugriff (PDF)

Abstract 3313: Pharmacologic targeting of Aurora-A kinase restores ER expression and endocrine sensitivity through impairment of breast cancer stemness

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3313-3313

2016

Volltextzugriff (PDF)

Abstract 3313: Pharmacologic targeting of Aurora-A kinase restores ERα expression and endocrine sensitivity through impairment of breast cancer stemness

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3313-3313

2016

Volltextzugriff (PDF)

Abstract PD7-06: A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD7-06-PD7-06

2020

Volltextzugriff (PDF)

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial

Investigational new drugs, 2005-10, Vol.23 (5), p.495-503

2005

Volltextzugriff (PDF)

Abstract P3-11-04: Endoxifen Downregulates AKT Phosphorylation Through Protein Kinase C Beta 1 in ER+/HER2- Breast Cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P3-P3-11-04

2023

Volltextzugriff (PDF)

Abstract 3769: Metabolic activation of batracylin and N-acetylbatracylin to reactive metabolites that bind protein and DNA: Possible role in toxicity

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3769-3769

2012

Volltextzugriff (PDF)

Abstract 3781: Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparative in vivo activity studies

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3781-3781

2012

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(21)
Oncology
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Female
(14)
Antineoplastic Agents
(13)
Pharmacology. Drug Treatments
(13)
Pharmacology & Pharmacy
(11)
Animals
(8)
Male
(8)
Adult
(7)
Breast Neoplasms - Drug Therapy
(7)
Aged
(6)
Chemotherapy
(6)
Middle Aged
(6)
Antineoplastic Agents - Pharmacokinetics
(5)
Antineoplastic Agents - Pharmacology
(5)
Breast Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies

Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies

Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells

Activation of the Antitumor Agent Aminoflavone (NSC 686288) Is Mediated by Induction of Tumor Cell Cytochrome P450 1A1/1A2

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans

Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1

Abstract P6-04-06: Protein kinase C beta 1 (PKCβ1), a novel drug target of Z-endoxifen, inhibits growth of estrogen receptor positive (ER+) breast cancer via activation of the NF-kB transcription factor RelA

Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)

Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

Abstract 3313: Pharmacologic targeting of Aurora-A kinase restores ER expression and endocrine sensitivity through impairment of breast cancer stemness

Abstract 3313: Pharmacologic targeting of Aurora-A kinase restores ERα expression and endocrine sensitivity through impairment of breast cancer stemness

Abstract PD7-06: A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial

Abstract P3-11-04: Endoxifen Downregulates AKT Phosphorylation Through Protein Kinase C Beta 1 in ER+/HER2- Breast Cancer

Abstract 3769: Metabolic activation of batracylin and N-acetylbatracylin to reactive metabolites that bind protein and DNA: Possible role in toxicity

Abstract 3781: Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparative in vivo activity studies

Suchergebnisse filtern